Welcome to our dedicated page for Adicet Bio SEC filings (Ticker: ACET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adicet Bio, Inc. (ACET) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biotechnology company, Adicet uses these filings to report on its allogeneic gamma delta CAR T cell programs in autoimmune diseases and cancer, capital raising transactions, and key corporate actions.
Investors can review Form 8-K current reports in which Adicet describes material events such as preliminary Phase 1 data for ADI-001/prulacabtagene leucel in lupus nephritis and systemic lupus erythematosus, updates on enrollment across additional autoimmune indications, strategic pipeline prioritization and discontinuation of ADI-270, and development plans for the ADI-212 solid tumor program. Other 8-K filings cover registered direct offerings of common stock and pre-funded warrants, Nasdaq bid price notices and market transfers, and workforce reduction decisions.
The company’s proxy materials, such as the definitive proxy statement on Schedule 14A for a special meeting of stockholders, outline proposals including amendments to the certificate of incorporation to effect a reverse stock split within a specified range and potential adjournments to solicit additional proxies. These documents detail how stockholders can vote, participate in virtual meetings, and understand the rationale for capital structure changes.
On Stock Titan, ACET filings are updated in near real time as they appear on EDGAR. AI-powered summaries highlight the main points of lengthy documents, helping readers quickly identify topics such as clinical data disclosures, financing terms, reverse stock split mechanics, and listing compliance discussions. Users can also locate quarterly and annual reports when filed (Forms 10-Q and 10-K), as well as any Form 4 insider transaction reports, to build a more complete picture of Adicet Bio’s financial condition, governance, and progress in advancing its gamma delta CAR T pipeline.
Adicet Bio, Inc. reported that Chief Financial Officer Brian Nicholas received a grant of stock options covering 43,361 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036. According to the vesting terms, 1/48th of the options vest on each monthly anniversary of the grant over forty-eight months, as long as he continues his service relationship with the company. Following this grant, he holds 43,361 stock options directly.
Adicet Bio, Inc. reported that President & CEO Chen Schor received a grant of stock options representing the right to buy 468,555 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036.
This award is compensation-related and not an open-market share purchase or sale. The filing notes that one forty-eighth of the options vest each month over 48 months from the grant date, contingent on Mr. Schor continuing his service with the company.
Adicet Bio Chief Medical Officer Julia D. Maltzman was granted stock options covering 72,555 shares of Common Stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036. This is a compensation-related award rather than an open-market share purchase.
The filing shows these are held directly and represent 72,555 option shares following the transaction. According to the terms, one forty-eighth of the options vest monthly over 48 months from the grant date, as long as she continues her service with the company.
Adicet Bio, Inc. reported that Chief Technology Officer Don Healey received a grant of stock options covering 43,361 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036. According to the terms, 1/48th of the options vest on each of the 48 monthly anniversaries of the grant date, as long as he continues his service with the company. This is a compensation-related award rather than an open-market share purchase.
Adicet Bio, Inc. Chief Scientific Officer Aftab Blake received a grant of stock options to acquire 72,555 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036.
According to the vesting terms, 1/48th of the options vest on each monthly anniversary over the next forty-eight months, as long as Blake continues a service relationship with the company. This is a compensation-related award, not an open-market purchase or sale, and it brings Blake’s directly held option position in this grant to 72,555 derivative securities.
Adicet Bio, Inc. files a shelf registration to offer up to $250,000,000 of common stock, preferred stock, debt securities, warrants and/or units, to be sold from time to time in one or more offerings.
The shelf permits offerings in various combinations and will be accompanied by prospectus supplements that specify amounts, prices and terms. The company notes Nasdaq listing under the symbol ACET and cites a March 11, 2026 closing price of $7.47 per share.
Adicet Bio, Inc. is a clinical-stage biotechnology company focused on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Its lead candidate, prula-cel, targets CD20 and is in an ongoing Phase 1 program across lupus nephritis, systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis and other autoimmune indications.
The FDA has granted Fast Track designations for prula-cel in relapsed/refractory class III or IV lupus nephritis, refractory SLE with extrarenal involvement and systemic sclerosis, and recently allowed outpatient dosing for lupus nephritis and SLE. Adicet plans a potential pivotal study in lupus nephritis, or lupus nephritis and SLE, starting in the second half of 2026, subject to regulatory clearance.
The company is also advancing ADI-212 for metastatic castration-resistant prostate cancer, aiming to file in the third quarter of 2026 and begin enrollment in the fourth quarter of 2026. A 1-for-16 reverse stock split was effected in December 2025, and as of March 10, 2026, 9,596,407 common shares were outstanding.
Adicet Bio reported continued investment in its pipeline alongside steady operating losses for the quarter and year ended December 31, 2025. In the fourth quarter, research and development expenses were $25.0 million and general and administrative costs were $6.9 million, leading to a net loss of $30.5 million, or $2.94 per share.
For full-year 2025, R&D spending was $99.1 million and G&A was $23.0 million, resulting in a net loss of $116.8 million, or $16.95 per share. Cash, cash equivalents and short-term investments totaled $158.5 million at year-end, and the company expects this to fund operations into the second half of 2027.
Operationally, Adicet highlighted strong enrollment in its Phase 1 autoimmune trial of prulacabtagene leucel (prula-cel), with clinical updates planned in the first and second halves of 2026, and FDA alignment enabling outpatient dosing for lupus nephritis and systemic lupus erythematosus. A Phase 1 study in treatment-refractory rheumatoid arthritis is underway, with another update expected in the second half of 2026.
The company is also advancing ADI-212 for metastatic castration-resistant prostate cancer, planning a regulatory filing in the third quarter of 2026 and expecting Phase 1 enrollment to begin in the fourth quarter of 2026, subject to regulatory clearance.
Adicet Bio reported an updated ownership filing showing that RA Capital Management and affiliated entities beneficially own 960,237 shares of Adicet Bio common stock. This represents approximately 9.99% of the company’s outstanding shares as of December 31, 2025, just after a 16-for-1 reverse stock split.
The RA Capital Healthcare Fund directly holds 948,249 shares plus pre-funded warrants exercisable for up to 1,152,833 additional shares. However, a “Beneficial Ownership Blocker” in the warrants prevents exercises that would push the group’s stake above 9.99%, so only 11,988 warrant shares are currently counted toward beneficial ownership.
RA Capital serves as investment adviser to the fund and may be deemed a beneficial owner for reporting purposes. The filing states that the securities were not acquired to change or influence control of Adicet Bio and that several reporting persons disclaim beneficial ownership except for meeting disclosure obligations.